Group B streptococcal infection medical therapy
|
Group B Streptococcal Infection Microchapters |
|
Differentiating Group B Streptococcal Infection from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Group B streptococcal infection medical therapy On the Web |
|
American Roentgen Ray Society Images of Group B streptococcal infection medical therapy |
|
Directions to Hospitals Treating Group B streptococcal infection |
|
Risk calculators and risk factors for Group B streptococcal infection medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]
Overview
Medical Therapy in Meningitis
Empirical Antibiotic Therapy in Neonatal Meningitis
GBS should be suspected as a causative agent for bacterial meningitis in infants less than two years of age for whom empirical antibiotic therapy should be initiated immediately.
| Age | Possible pathogens causing the bacterial meningitis | Empirical treatment |
| < 1 month | Streptococcus agalactiae Escherichia coli Listeria monocytogenes Klebsiella |
Ampicillin + cefotaxime OR Ampicillin + aminoglycoside |
| 1-23 months | Streptococcus pneumoniae Neisseria meningitidis Streptococcus agalactiae Haemophilus influenzae E. coli |
Vancomycin + third generation cephalosporin |
Targeted Antibiotic Therapy in Neonatal Meningitis
| Recommended therapy for GBS meningitis | Alternative therapy for GBS meningitis |
| Ampicillin OR Penicillin Consider adding an aminoglycoside |
Third generation cephalosporin (Ceftriaxone or cefotaxime) |
Recommended Dosage of Antibiotics
| Antibiotic agent | Dosage |
| Ampicillin | 0-7 days: 150 mg/kg 8-28 days: 200 mg/kg Infants > 28 days: 300 mg/kg |
| Cefotaxime | |
| Ceftriaxone | |
| Gentamicin | |
| Amikacin | |
| [[Tobramycin | |
| Penicillin | |
| Vancomycin | |
| Ceftriaxone | |
| Ceftazidime |